Conjugation of carrier proteins to polysaccharide antigens is an effective strategy to enhance the immunogenicity of poorly immunogenic polysaccharides. This conjugation method has been successfully applied to the development of polysaccharide conjugate vaccines. Through covalent linkage, the protein antigen on the polysaccharide is improved and the immunogenicity of the polysaccharide is enhanced. This involves the selection of carrier proteins and polysaccharide antigens as well as conjugation techniques.
Fig.1 Production of conjugate vaccines. (Ihssen, et al., 2010)
As a professional company for polysaccharide-carrier protein conjugation, CD BioGlyco provides carrier protein design, polysaccharide antigen production, and polysaccharide conjugation technology services.
Carrier proteins carry human T-cell epitopes and convert T-cell-independent immune responses to polysaccharides into T-helper cell responses would be suitable carriers for polysaccharide-conjugated vaccines. However, the availability of such carrier proteins is limited. Therefore, it is crucial to develop new vaccine carriers in addition to the traditional protein carriers. The production of polysaccharide antigens presents technical challenges that require attention. Moreover, the conjugation technology based on physical and chemical principles plays a vital role in the successful preparation of conjugates.
Several factors influence the immunogenicity of polysaccharide conjugates, including the sugar length, sugar amount, sugar type, charge of the non-reducing end, conjugation chemistry, and linker used for conjugation. The optimal immune response varies depending on the specific vaccine candidate, requiring an appropriate sugar length. It is important for the sugar size to adequately represent the natural antigenic epitope. Furthermore, the addition of adjuvants is considered to enhance the immunogenicity of polysaccharide conjugate vaccines. In the process of designing polysaccharide conjugates, we will consider the following points:
Fig.2 Factors to consider when designing polysaccharide conjugates. (CD BioGlyco)
CD BioGlyco aims to provide customers with unparalleled support for the Development of Carbohydrate-based Vaccines. We provide integrated one-stop solutions for polysaccharide conjugation. For decades, we have won the trust of global scientists with high-quality products, services, and technical support. If you are interested in our services, please contact us for more details without any hesitation.
Reference:
